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ABSTRACT
The IUPHAR database (IUPHAR-DB) integrates peer-
reviewed pharmacological, chemical, genetic, func-
tional and anatomical information on the 354 non-
sensory G protein-coupled receptors (GPCRs), 71
ligand-gated ion channel subunits and 141 voltage-
gated-like ion channel subunits encoded by the
human, rat and mouse genomes. These genes repre-
sent the targets of approximately one-third of cur-
rently approved drugs and are a major focus of drug
discovery and development programs in the phar-
maceutical industry. IUPHAR-DB provides a com-
prehensive description of the genes and their
functions, with information on protein structure and
interactions, ligands, expression patterns, signaling
mechanisms, functional assays and biologically
important receptor variants (e.g. single nucleotide
polymorphisms and splice variants). In addition, the
phenotypes resulting from altered gene expression
(e.g. in genetically altered animals or in human
genetic disorders) are described. The content of
the database is peer reviewed by members of the
International Union of Basic and Clinical Pharmacol-
ogy Committee on Receptor Nomenclature and Drug
Classification (NC-IUPHAR); the data are provided
through manual curation of the primary literat-
ure by a network of over 60 subcommittees of
NC-IUPHAR. Links to other bioinformatics
resources, such as NCBI, Uniprot, HGNC and the
rat and mouse genome databases are provided.
IUPHAR-DB is freely available at http://www.
iuphar-db.org.
INTRODUCTION
One-third of the medicinal drugs in current use and many
drugs of abuse target members of three protein superfam-
ilies: nonsensory G protein-coupled receptors (GPCRs),
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voltage-gated-like ion channels (VGICs) and ligand-gated
ion channels (LGICs) (1). These proteins, encoded by
570 genes, encompass an estimated 20% of all likely
drug targets and are, therefore, a focus of intense research
in academia and in industry. The International Union of
Basic and Clinical Pharmacology Committee on Receptor
Nomenclature and Drug Classiﬁcation (NC-IUPHAR;
http://www.iuphar.org/nciuphar.html) has, since 1992,
issued guidelines for receptor and ion channel nomencla-
ture and for classifying the major receptor and ion channel
systems. More recently, an important part of the mission
of NC-IUPHAR has been to facilitate the characterization
of new functional receptors and ion channels identiﬁed by
sequencing of the human, rat and mouse genomes. In
addition to publishing a series of reviews on these issues
(http://www.iuphar.org/nciuphar_arti.html), the commit-
tee has, since 2000, worked to create a database of
GPCRs and ion channels containing peer-reviewed infor-
mation on the pharmacology, genetics, function and dis-
tribution of these proteins.
GPCRs, also known as seven-transmembrane domain
(7TM) receptors because of their characteristic topology,
comprise one of the largest protein superfamilies in mam-
mals (2) and are found in a range of eukaryote taxa. The
binding of extracellular ligands (e.g. hormones and neuro-
transmitters) leads to a conformational change resulting in
the activation of intracellular heterotrimeric guanine
nucleotide-binding proteins (G proteins) which, in turn,
regulate numerous signaling pathways including the pro-
duction or liberation of intracellular second messengers,
such as cyclic AMP, 1,2-diacylglycerol, inositol 1,4,5-
trisphosphate and Ca2+, control of VGIC function and
assembly of signal-transduction complexes. GPCRs regu-
late a wide range of physiological functions, such as hor-
mone secretion, neurotransmitter release, smooth muscle
relaxation/contraction, cell apoptosis, immune defense,
chemotaxis, cell aggregation, nociception, learning and
behavior, neuroplasticity, regulation of sleep-wakefulness
cycles and food intake. It is currently estimated that there
are 354 ‘nonsensory’ GPCRs (i.e. excluding those mediat-
ing vision, taste and olfaction) in humans. Of these, 214
are assigned endogenous ligands with the remainder clas-
siﬁed as ‘orphan’ receptors, which are proteins that exhibit
the characteristic 7TM topology but for which no endo-
genous ligand has yet been identiﬁed. ‘Reverse pharmacol-
ogy’ (3) is progressively allowing ‘deorphanisation’ of
these receptors by assigning endogenous ligands and phy-
siological functions to them (4).
The VGIC superfamily includes 10 families that share a
common cation-selective pore-forming module composed
of two transmembrane segments and an intervening P
loop (5). The voltage-gated Na+ (NaV) and Ca
2+ (CaV)
channels are the most structurally complex. These single
ion channel subunits have four repeating domains that
each contains six transmembrane segments yielding 24
transmembrane segments in all. In each domain, segments
S1–S4 comprise a regulatory module that confers voltage
sensitivity, and segments S5 and S6 and the P loop line the
central pore. In addition to their primary regulation by
voltage on the millisecond time scale, these channels
have slower secondary regulation by numerous
signaling pathways. Members of the two-pore channel
family (TPC), whose functional properties are unknown,
are composed of two separate subunits that each have two
linked domains with six transmembrane segments, similar
to the homologous domains of NaV and CaV channels.
Five ion channel families are tetramers of subunits that
each has a structure homologous to one domain of a NaV
or CaV channel. Voltage-gated K
+ channels (KV) are pri-
marily regulated by voltage and secondarily by G proteins
and second-messenger signaling pathways. Ca2+-activated
K+ channels (KCa), transient receptor potential channels
and hyperpolarization- and cyclic-nucleotide-gated ion
channels are jointly regulated by voltage, membrane
lipids and intracellular ligands. Cyclic-nucleotide-gated
ion channels are primarily regulated by cyclic nucleotides,
even though their S1–S4 segments are similar in structure
to the voltage-gated channels. Finally, the two structurally
simplest VGICs have only pore-forming domains.
Inwardly rectifying K+ channels (Kir) are composed of
tetramers of subunits having two transmembrane seg-
ments with an intervening P loop. Two-P K+ channels
(K2P) are composed of dimers of subunits having two
linked pore-forming motifs, each similar to the Kir chan-
nels. Kir and K2P channels are regulated by membrane
lipids and intracellular ligands, including G proteins and
small molecules such as Mg2+, polyamines and ATP.
Diversity within this large protein superfamily is increased
by association of the principal pore-forming subunits with
one or more auxiliary subunit and by formation of hetero-
oligomers of the pore-forming subunits of the family
members that function as tetramers.
LGICs, unlike GPCRs, incorporate the ligand-binding
site and eﬀector (i.e. ion channel) within a common multi-
meric complex. They are the mediators of fast, phasic,
synaptic transmission in the nervous system and at the
skeletal neuromuscular junction. In addition, some
LGICs underlie a tonic form of synaptic transmission in
the central nervous system and their distribution and func-
tions are not limited to excitable cells. The LGICs form
three superfamilies on the basis of homology in the amino
acid sequences and topology of their component subunits,
namely the pentameric Cys-loop, and the cation-selective
ionotropic glutamate and P2X receptors, which assemble
as tetramers and trimers, respectively. The Cys-loop recep-
tors comprise the cation-selective nicotinic acetylcholine
and 5-hydroxytryptamine type-3 (5-HT3) receptors (with
17 and 5 subunits, respectively, encoded by distinct genes)
and the anion-selective GABAA (19 subunits) and glycine
receptors (ﬁve subunits) (6–9). A cation-selective zinc-
activated channel forms an additional member of the
Cys-loop superfamily (10). Ionotropic glutamate receptors
comprise the N-methyl-D-aspartate (seven subunits),
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(four subunits) and kainate (ﬁve subunits) receptor classes.
Two orphan subunits have also been cloned (11). The P2X
receptor subunits are P2X1 through to P2X7 (12).
Several other databases contain information on GPCRs
and ion channels. The NIMH-PDSP Ki Database (http://
pdsp.med.unc.edu/pdsp.php), DrugBank (13) and Bind-
ingDB (14) each contain data on the interaction of small
molecule ligands with known or potential drug targets.
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PharmGKB (15) is a pharmacogenetics and pharmacoge-
nomics resource with coverage of many of the drugs and
drug targets in IUPHAR database (IUPHAR-DB).
GLIDA (GPCR-ligand database) (16) contains biological
information on GPCRs and chemical information on their
known ligands. GPCRdb (17) contains cDNA and amino
acid sequences, multiple sequence alignments, phyloge-
netic trees and structural models of GPCRs, the GPCR
NaVa database (18) describes naturally occurring
sequence variation in human GPCRs and gpDB (G pro-
tein database) (19) is a database of G proteins and their
interactions with GPCRs and eﬀector molecules. The
Endogenous GPCR List (http://www.tumor-gene.org/
GPCR/) tabulates the GPCRs expressed endogenously
in various cell lines. There are two databases of olfactory
receptors (the largest multigene family in multicellular
organisms): HORDE (The Human Olfactory Data
Explorer) (20) and the Olfactory Receptor Database
(21); these are sensory GPCRs and are, therefore, outside
the scope of IUPHAR-DB. There are few databases con-
cerned with LGICs and VGICs in the public domain.
VKCDB, the voltage-gated potassium channel database
(22), contains protein sequences and electrophysiological
and pharmacological data on voltage-gated potassium
channels and LGICdb (23) contains nucleic acid and pro-
tein sequences, multiple sequence alignments, phyloge-
netic trees and structural information on LGIC subunits.
IUPHAR-DB complements existing databases by pro-
viding a richly curated overview of the biology of GPCRs
and ion channels, underpinned by rigorous peer-review by
NC-IUPHAR and its network of 60 subcommittees of
international experts.
CONSTRUCTION AND CONTENT
IUPHAR-DB is implemented as aMySQL relational data-
base (http://www.mysql.com) containing information on
GPCRs and a PostgreSQL relational database (http://
www.postgresql.org) holding data on VGICs and LGICs.
Data are submitted and edited using an in-house editing
tool written in Java and using JDBC to map the biological
objects to the database. To ensure that data remain consis-
tent between databases, the editing tool retrieves citations
directly from the PubMed database (http://www.ncbi.nlm.
nih.gov/pubmed). The public web interface uses Java serv-
lets, Java Server Pages and JDBC to provide free online
access to the entire public database. The public interface
runs in the Tomcat servlet container on a Linux platform.
IUPHAR-DB contains information on the GPCRs,
VGICs and LGICs (‘drug targets’) encoded by the
human, mouse and rat genomes. In accordance with
IUPHAR guidelines, GPCRs and LGICs are grouped
into families according to their endogenous ligands
(24,25), whereas VGICs are grouped according to a
phylogenetically based classiﬁcation scheme (5).
NC-IUPHAR has a network of over 60 expert subcom-
mittees, each committee being responsible for developing
the nomenclature for their receptor. The compilation of
the data submitted to the database is, in most cases, coor-
dinated by members of the relevant subcommittee.
Where no relevant subcommittee exists, data are captured
by the curators or individual experts and peer reviewed by
at least two external expert referees. Data are sourced from
and referenced to the primary literature (original articles in
peer-reviewed publications rather than review articles),
with links to citations in PubMed. Wherever possible,
data are supported by more than one literature source.
After review by the curators to ensure accuracy and con-
sistency with the rest of the information in the database,
the data are added to the production server and transferred
to the public database, after approval by NC-IUPHAR
(updates normally take place twice a year following
NC-IUPHAR executive committee meetings). Data are
reviewed at regular intervals (at least yearly) by subcom-
mittees and other contributors and updated as necessary.
Data on each gene in the database can be displayed on
an individual page containing the following information:
(1) Approved IUPHAR nomenclature alongside alterna-
tive or outdated names for the receptor or channel.
(2) Structural and genomic data linked to its sources in
the HUGO Gene Nomenclature Committee (HGNC)
(26), Mouse Genome Informatics (MGI) (27), Rat
Genome (28) and Refseq protein (29) databases.
(3) Links to papers describing the ﬁrst cloning of each
receptor or ion channel cDNA and gene.
(4) Links to other databases including Entrez Gene (30),
GeneCards (31) and OMIM (32).
The database contains support for heterooligomers com-
posed of two or more GPCR (33) or ion channel subunits,
for example GABAB receptor heterodimers (34) and for
complexes of receptors or channels with accessory proteins,
for example the multiple pharmacologically distinct recep-
tor subtypes that are generated by association of receptor
activity-modifying proteins with the calcitonin-receptor-
like receptor and the calcitonin receptor (35–37). On
pages describing such complexes, there is a
subunit table with links to database pages describing the
properties of the constituent subunits or accessory proteins.
The following curated and peer-reviewed information is
provided for all genes in the database (with the exception,
at present, of some orphan GPCRs):
(1) Tissue distribution of gene expression at the levels of
mRNA, protein and radioligand binding, focusing on
the adult.
(2) Tissue function (physiological responses mediated by
the receptor or ion channel).
(3) Functional assays (whole tissue or isolated cell sys-
tems in which a pharmacological response can be
ﬁrmly attributed to the function of a deﬁned receptor
or ion channel).
(4) Physiological consequences of altering gene expres-
sion (e.g. in knockout and transgenic animals).
(5) Functionally important receptor variants (e.g. poly-
morphisms, mutations and splice variants, which
have been demonstrated to alter receptor function).
(6) Tables of aﬃnity data for selected ligands.
Only selected ligands are displayed in the database. These
groups include drugs that are potent and selective and/or
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used as prescription medications, endogenous ligands (e.g.
5-HT as an endogenous substance that acts through 5-HT
receptors) and radiolabeled substances that can be
employed in radioligand binding studies. In addition,
ligands important for understanding structure–activity
relationships for a drug target or a family of receptors
or ion channels are included. Where possible, data for
these index compounds are included for all members of
the receptor or ion channel family.
When possible, the database cites estimates of the equi-
librium dissociation constant (KD) for each ligand at the
cloned human receptor or channel expressed in a trans-
fected cell line, determined in a binding assay using a radi-
olabeled antagonist as tracer. When such data are lacking,
results obtained from other species and/or from other
assay systems are reported. If possible, data are obtained
from more than one publication and a range of values is
displayed together with multiple citations. Where avail-
able, alternative ligand names are displayed and links are
provided to the relevant entry in the PubChem compound
database (38) and to a table listing the potency of the
ligand at all other reported receptors and channels in
IUPHAR-DB. Tables of ligands can be sorted, for exam-
ple, alphabetically by name, by activity, by aﬃnity or by
the units in which aﬃnity data are provided.
Online Supplementary Figure 1 is an interactive PDF
ﬁle illustrating the main features of a database page for a
GPCR. These pages contain tables of ligands classiﬁed as
agonists (full or partial), antagonists, inverse agonists or
allosteric regulators (positive, negative or neutral) (39).
Details of primary and secondary transduction mecha-
nisms are given, listing the G proteins involved and the
downstream response to receptor activation.
Although there is evidence that some VGICs may exist
as heterooligomeric complexes with distinct pharmaco-
logical properties, IUPHAR-DB presently provides
information on individual VGIC genes and the properties
of homomeric channels. Quantitative data are included
for the voltage dependence of activation and inactivation,
single-channel conductance and binding of drugs and
neurotoxins (classiﬁed as activators, gating inhibitors or
pore blockers), focusing on agents that are widely
used and that are diagnostic of channel identity and
function.
In the case of the LGICs, which, in contrast to VGICs,
do not generally assemble and function as homomers, the
characteristics of individual receptors of deﬁned subunit
composition are presented. The data presented comprise
entries concerning ion selectivity, conductance and voltage
dependence, agonists, antagonists, channel blockers, allos-
teric regulators and functional assays.
The web interface includes a comprehensive search
facility to enable text-based searches of drug targets and
ligands. Searches are, by default, across all ﬁelds in the
database; alternatively, searches can be focused by select-
ing one or more ﬁelds (e.g. searching for a receptor name
or alias). Alphabetical lists of receptor and ion channel
families are available via a menu on the page sidebar,
which links to individual receptor or channel database
pages.
ADDITIONAL FILES
There is an introductory article for each receptor and ion
channel family, which reviews the properties, nomencla-
ture and classiﬁcation of each receptor and channel
family. Curated lists of the genes encoding human,
mouse and rat GPCRs, VGICs and LGICs can be
viewed as HTML pages that list the approved IUPHAR
nomenclature, have links to the receptor or channel page
in the database, give the name of the primary endogenous
ligand or physiological ion, human, rat and mouse gene
names and provide links to the Entrez Gene database for
all three species. Alternatively, the gene lists can be down-
loaded as Microsoft Excel spreadsheets, which addition-
ally include the HGNC, RGD and MGI identiﬁers,
genomic location, RefSeq nucleotide and protein acces-
sion numbers and SwissProt and Entrez Gene identiﬁers
for human, rat and mouse.
The Evolving Pharmacology subcommittee of
NC-IUPHAR monitors the literature for reports of new
‘pairings’ of GPCRs with endogenous ligands, for exam-
ple, the recent emergence of estrogen as an endogenous
ligand for GPR30 (40). A webpage (http://www.iuphar-
db.org/latestPairings.jsp) gives details of recent develop-
ments in this area. A ‘hot topics’ page (http://www.iuphar-
db.org/hotTopics.jsp) contains brief summaries of impor-
tant developments in receptor and ion channel pharmacol-
ogy. An RSS feed (http://www.iuphar-db.org/feed.xml)
provides details of the latest items added to the database.
DISCUSSION AND FUTURE DIRECTIONS
The aim of the IUPHAR-DB project is to create a richly
annotated resource giving pharmacological, genetic, func-
tional and anatomical information on a subset of drug
targets that are of particular importance in the treatment
of disease and in the development of new medicines.
Uniquely, the content of the database is peer reviewed
by international experts and the drug targets are deﬁned
unambiguously using IUPHAR-approved nomenclature.
Only drugs that are potent and selective, used clinically
or are important in understanding structure–activity rela-
tionships are included.
The future development of IUPHAR-DB will include
the addition of further classes of drug targets, such as
the nuclear receptors (41) and receptor tyrosine kinases.
Reﬁnements to the database will include the provision of
more sophisticated search tools and the development of
‘ligand-centered’ pages, which will aggregate information
on the pharmacology of individual drugs, as an alternative
entry point to the database.
Although there are other databases that document
aspects of the molecular biology and pharmacology of
GPCRs and ion channels, IUPHAR-DB is the ﬁrst in
the public domain to integrate curated structural, physio-
logical, pathophysiological and quantitative pharmaco-
logical data across a wide range of drug targets.
Intended as an international resource for students, scien-
tists and the interested public, the website receives over
3500 unique visitors from 80 countries each month.
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DATA AVAILABILITY
IUPHAR-DB is freely available at http://www.iuphar-db.
org with online help at http://www.iuphar-db.org/
helpPage.jsp. SQL dumps of the datasets can be supplied
on request to curators@iuphar-db.org.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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